Miltefosine as a PPM1A activator improves AD-like pathology in mice by alleviating tauopathy via microglia/neurons crosstalk.
Brain Behav Immun Health
; 26: 100546, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36388134
AAV, Adeno-associated virus; AD, Alzheimer's disease; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; Akt, V-akt routine thymoma viral oncogene homolog; Alzheimer's disease; Aß, Amyloid-ß; CDK5, Cyclin-dependent protein kinase-5; CNS, Central nervous system; CX3CR1; CX3CR1, C-X3-C Motif Chemokine Receptor 1; CaMKII, Calcium/calmodulin-dependent protein kinase II; DYRK1A, Dual-specificity tyrosine phosphorylation-regulated kinase-1A; GSK3ß, Glycogen synthase kinase 3ß; LTP, Long-term potentiation; MST, Microscale thermophoresis; MWM, Morris water maze; Miltefosine; NF-kB, Nuclear factor-κb; NFTs, Neurofibrillary tangles; NLRP3; NLRP3, Nod-like receptor protein 3; NOR, New object recognition; PP2, Protein phosphatase 2; PPM1A; PPM1A, Phosphatase magnesium-dependent 1A; PSD95, Postsynaptic density protein 95; SYN, Synaptophysin; Tauopathy; fEPSPs, Field excitatory postsynaptic potentials
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2022
Tipo del documento:
Article